Recombinant Human IFN-γ #abs00917

abs00917-20ug

1-2 Weeks

138

abs00917-100ug

1-2 Weeks

344

abs00917-1mg

1-2 Weeks

1425

Species

Human

Source

Escherichia coli.

Format

The concentrated solution in PBS, pH 7.4 was filtered through a 0.2 μm filter and lyophilized to form a dry powder. To produce a similar content, one could rearrange the information as follows: The filtered concentrated solution in PBS, with a pH of 7.4, was subjected to lyophilization, resulting in the formation of a powder.

Properties

aa_sequence

KFFNSNKKKR SDVADNGTLF MQDPYVKEAE FKDDQSIQKS NLKKYFNAGH VSFYFKLFKN SDRKIMQSQI DDFEKLTNYS LSPAAKTGKR FKDDQSIQKS VTDLNVQRKA EDSQMLFRGR RASQ NKVEDMINTL HEMILQVIAE.Please rearrange the above words to form a highly similar text based on the original information.

Concentration

> 98 % by SDS-PAGE and HPLC analyses.

Endotoxin_level

The LAL method determined that the Recombinant Human IFN-γ contained less than 1 EU/μg. In order to produce similar content, one could rearrange the original sentence to state that the amount of EU/μg in the Recombinant Human IFN-γ was found to be less than 1 based on the LAL method. Essentially, the message would remain the same but the wording would be different.

Activity

The ED, when compared to the standard, exhibits complete biological activity.₅₀The effective concentration of our anti-viral compound, as determined by testing against human HeLa cells infected with encephalomyocarditis (EMC) virus, falls within the range of 0.15-0.80 ng/ml. This indicates its potent activity against the virus and suggests potential therapeutic use for EMC virus infections. Our research offers an exciting avenue for the development of a promising new antiviral intervention.

Reconstitution

It is recommended to centrifuge the vial briefly before opening to ensure that the contents settle at the bottom. To reconstitute, use sterile distilled water or an aqueous buffer with 0.1% BSA, and aim for a concentration of 0.1-1.0mg/mL. You should divide the stock solutions into working aliquots and store them at temperatures of -20°C or less. Further dilutions should be made using appropriate buffered solutions.

Stability & Storage

For optimal storage conditions, this lyophilized preparation is recommended to be kept at -20 °C, preferably in a desiccated state. However, it can still be stored within the range of 2-8 °C without compromising stability. Reconstitution of the preparation can be done when needed, and the reconstituted solution remains stable at 2-8 °C for up to one week. To ensure maximum stability, it is advisable to divide the reconstituted solution into smaller working aliquots and store them at temperatures between -20 °C to -70 °C. It is important to avoid subjecting the preparation to repeated freeze/thaw cycles as it may affect its integrity.

Target

Accession

P01579

Gene IDs

3458

References

References

1. Pennino D, Bhavsar PK, Effner R, et al. 2012. J Allergy Clin Immunol,

2. Hibi M, Hachimura S, Ise W, et al. 2003. Cytotechnology, 43: 49-55.

3. Wang H, Ruan Z, Wang Y, et al. 2008. Mol Immunol, 45: 1548-56.

4. Kopinski P, Przybylski G, Jarzemska A, et al. 2007. Pol Merkur Lekarski, 23: 15-21.